

Blinded phase: Optic and Ocular: Number of participants with disease control for 3 months

One (50.00%) of the 2 participants with disease control in the placebo group had both eyes eligible at baseline and did not have disease control in both eyes. Of the 23 participants in the adalimumab group with disease control, 5 participants (21.74%) had both eyes eligible at baseline and all 5 participants had disease control in both study eyes for at least three months.

Table 1: Disease control for at least three months in all eligible eyes

Treatment	Number randomised	Number with disease control, N (%)	Relative risk (95% CI)	Fisher's Exact Test P-value
Placebo	30	1 (3.33%)	11.50 (1.63, 81.12)	< 0.001
Adalimumab	60	23 (38.33%)		
Total	90	24 (26.67%)		